A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).

ABSTRACT:

Introduction

The protein-protein interaction PD1/PD-L1 is an important immune checkpoint and several recently approved monoclonal antibodies show promising anti cancer activities in the clinical practice. However, only a small percentage of cancer patients benefit from PD1/PD-L1 directed mAbs. Moreover, some patients experience immune related side effects upon treatment with these mAbs. Recently, several atomic-resolution structures of human PD1/PD-L1, and small molecules, peptides and mAbs with PD-L1 and PD1 open the field for structure based drug design. Small molecules and peptides targeting PD1/PD-L1 promise to enhance tumor activity while showing less immune related side effects.

Areas covered

We reviewed the small molecules classes and peptides targeting PD1/PD-L1.

SUBMITTER: Shaabani S 

PROVIDER: S-EPMC6323140 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature